Literature DB >> 2033678

Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection.

D L Lodmell1, J W Sumner, J J Esposito, W J Bellini, L C Ewalt.   

Abstract

Raccoon poxvirus (RCN) recombinants expressing the rabies virus internal structural nucleoprotein (RCN-N) protected A/WySnJ mice against a lethal challenge with street rabies virus (SRV). Maximum survival was achieved following vaccination by tail scratch and footpad (FP) SRV challenge. RCN-N-vaccinated mice inoculated in the FP with SRV were resistant to infection for at least 54 weeks postvaccination. Protection was also elicited by RCN recombinants expressing the rabies virus glycoprotein (RCN-G). Vaccination with RCN-G evoked rabies virus neutralizing antibody. Rabies virus neutralizing antibody was not detected in RCN-N-vaccinated mice prior to or following SRV infection. Radioimmunoprecipitation assays showed that sera from RCN-N-vaccinated mice which survived SRV infection did not contain antibody to SRV structural protein G, M, or NS. The mechanism(s) of N-induced resistance appears to correlate with the failure of peripherally inoculated SRV to enter the central nervous system (CNS). Support for this correlation with resistance was documented by the observations that SRV-inoculated RCN-N-vaccinated mice did not develop clinical signs of CNS rabies virus infection, infectious SRV was not detected in the spinal cord or brain following FP challenge, and all RCN-N-vaccinated mice died following direct intracranial infection of the CNS with SRV. These results suggest that factors other than anti-G neutralizing antibody are important in resistance to rabies virus and that the N protein should be considered for incorporation with the G protein in recombinant vaccines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033678      PMCID: PMC241005     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein.

Authors:  H Bunschoten; M Gore; I J Claassen; F G Uytdehaag; B Dietzschold; W H Wunner; A D Osterhaus
Journal:  J Gen Virol       Date:  1989-02       Impact factor: 3.891

2.  Antiviral activity of monoclonal antibodies specific for the internal proteins N and NS of rabies virus.

Authors:  M Lafon; M Lafage
Journal:  J Gen Virol       Date:  1987-12       Impact factor: 3.891

3.  Completion of the rabies virus genome sequence determination: highly conserved domains among the L (polymerase) proteins of unsegmented negative-strand RNA viruses.

Authors:  N Tordo; O Poch; A Ermine; G Keith; F Rougeon
Journal:  Virology       Date:  1988-08       Impact factor: 3.616

4.  Use of recombinant vaccinia-rabies virus for oral vaccination of fox cubs (Vulpes vulpes, L) against rabies.

Authors:  B M Brochier; B Languet; J Blancou; M P Kieny; J P Lecocq; F Costy; P Desmettre; P P Pastoret
Journal:  Vet Microbiol       Date:  1988-10       Impact factor: 3.293

5.  Murine T cell clones directed to rabies virus: isolation and some of their properties.

Authors:  S Cho; H Narahara; K Mifune; A Kawai
Journal:  J Gen Virol       Date:  1987-04       Impact factor: 3.891

6.  Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein.

Authors:  J J Esposito; J C Knight; J H Shaddock; F J Novembre; G M Baer
Journal:  Virology       Date:  1988-07       Impact factor: 3.616

7.  Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies.

Authors:  J Esposito; K Brechling; G Baer; B Moss
Journal:  Virus Genes       Date:  1987-11       Impact factor: 2.332

8.  Recombinant fowlpox virus inducing protective immunity in non-avian species.

Authors:  J Taylor; R Weinberg; B Languet; P Desmettre; E Paoletti
Journal:  Vaccine       Date:  1988-12       Impact factor: 3.641

9.  Efficacy of influenza haemagglutinin and nucleoprotein as protective antigens against influenza virus infection in mice.

Authors:  M E Andrew; B E Coupar
Journal:  Scand J Immunol       Date:  1988-07       Impact factor: 3.487

10.  Recognition of rabies and rabies-related viruses by T cells derived from human vaccine recipients.

Authors:  E Celis; D Ou; B Dietzschold; H Koprowski
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

View more
  12 in total

1.  Immunogenicity and relative attenuation of different vaccinia-rabies virus recombinants.

Authors:  J H Zhu; J Wang; B Cai; W Zhao; Y Zhu; R Chao; L Chen; H Xue; B L Ying; C P Li; Q L Hu; J Sha; J J Esposito
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

2.  A new competitive enzyme-linked immunosorbent assay demonstrates adequate immune levels to rabies virus in compulsorily vaccinated Japanese domestic dogs.

Authors:  M Sugiyama; R Yoshiki; Y Tatsuno; S Hiraga; O Itoh; K Gamoh; N Minamoto
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

3.  Expression of the nucleoprotein of rabies virus in Escherichia coli and mapping of antigenic sites.

Authors:  H Goto; N Minamoto; H Ito; T R Luo; M Sugiyama; T Kinjo; A Kawai
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Resistance of mice vaccinated with rabies virus internal structural proteins to lethal infection.

Authors:  Y Takita-Sonoda; H Fujii; K Mifune; Y Ito; M Hiraga; A Nishizono; K Mannen; N Minamoto
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

5.  Rabies virus antinucleoprotein antibody protects against rabies virus challenge in vivo and inhibits rabies virus replication in vitro.

Authors:  D L Lodmell; J J Esposito; L C Ewalt
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

6.  Cross-protection of mice against a global spectrum of rabies virus variants.

Authors:  D L Lodmell; J S Smith; J J Esposito; L C Ewalt
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice.

Authors:  U Steinhoff; U Müller; A Schertler; H Hengartner; M Aguet; R M Zinkernagel
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

8.  Raccoon poxvirus rabies virus glycoprotein recombinant vaccine in sheep.

Authors:  J C DeMartini; H M Bickle; S J Brodie; B X He; J J Esposito
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

9.  Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.

Authors:  Laura Evgin; Markus Vähä-Koskela; Julia Rintoul; Theresa Falls; Fabrice Le Boeuf; John W Barrett; John C Bell; Marianne M Stanford
Journal:  Mol Ther       Date:  2010-02-16       Impact factor: 11.454

10.  Expression of the rabies virus nucleoprotein in plants at high-levels and evaluation of immune responses in mice.

Authors:  Irene Perea Arango; Elizabeth Loza Rubio; Edith Rojas Anaya; Teresa Olivera Flores; Luis Gonzalez de la Vara; Miguel Angel Gómez Lim
Journal:  Plant Cell Rep       Date:  2008-02-13       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.